Ritonavir-boosted lopinavir

DRUG4 trials

Sponsors

Kirby Institute, Bamrasnaradura Infectious Diseases Institute, University of Aarhus, Centre Hospitalier Universitaire Saint Pierre

Conditions

AIDSHIVHIV InfectionsHIV-1HIV-1 InfectionLopinavirTreatment Failure

Phase 4

A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen

CompletedNCT00931463

Kirby InstituteHIV Infections

Start: 2009-09-01End: 2013-08-01Updated: 2026-03-27

Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure

CompletedNCT01189695

Bamrasnaradura Infectious Diseases InstituteAIDS, HIV, Lopinavir +1

Start: 2010-12-31End: 2013-01-31Updated: 2013-05-13

PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial

CompletedNCT01192035

University of AarhusHIV-1

Start: 2011-05-31End: 2014-09-30Updated: 2015-06-25

Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting

CompletedNCT01772940

Centre Hospitalier Universitaire Saint PierreHIV-1 Infection

Start: 2008-12-31End: 2011-12-31Updated: 2013-08-26

Related Papers

Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection

PLoS ONE2015-02-2743 citations

HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy

PLoS ONE2013-10-3017 citations

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.

2013-06-01119 citations